Autophagy and Ocular Toxoplasmosis
自噬和眼弓形虫病
基本信息
- 批准号:10391468
- 负责人:
- 金额:$ 37.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAntibodiesAutophagocytosisAutophagosomeBlindnessCellsChildConfocal MicroscopyDepositionDiseaseEGF-Like DomainEGFR inhibitionElderlyElectron MicroscopyEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEventGalactose Binding LectinGeneticImpairmentInfectionLeadMediatingMembraneMicrobeMolecularMusOcular ToxoplasmosisOutcomeParasitesPathogenesisPathway interactionsPatientsPenetrationPharmacologyPhosphorylationPhosphotransferasesProcessProtein KinaseProteinsRecurrent diseaseRelapseResistanceRetinaRetinitisRoleSTAT3 geneSignal PathwaySignal TransductionTestingTherapeuticToxoplasma gondiiToxoplasmosisTransactivationTransgenic MiceUbiquitinVacuoleVisionVisualWorkcongenital infectionimmunosuppressedimprovedin vivoinhibitorlive cell microscopynovelnovel therapeutic interventionpathogenpreventprotective effectprotein activationprotein expressionrecruittherapeutic target
项目摘要
The intracellular protozoan Toxoplasma gondii is the most common cause of infectious retinitis in
the world. Ocular toxoplasmosis tends to recur and leads to vision loss in 25% of patients, especially
in children with congenital infection, the elderly and the immunosuppressed. Current treatment does
not improve visual function or prevent relapses. A better understanding of the mechanisms that
control ocular toxoplasmosis may result in novel therapeutic approaches against this disease.
Autophagy is a constitutive process of lysosomal degradation. T. gondii must avoid targeting by
autophagy in order to survive within host cells. We showed that during invasion of host cells, T. gondii
induces EGFR signaling that results in avoidance of initial autophagic targeting. Recently, we found
that T. gondii causes sustained Src signaling that maintains activation of EGFR and Akt (inhibitor of
autophagy). Pharmacologic inhibition of EGFR triggers autophagic killing of T. gondii in previously
infected cells and protects against ocular toxoplasmosis. However, the protection is partial (EGFR
expression is restricted; EGFR is only partially responsible for Akt activation). In contrast, Src is
ubiquitous and low concentrations of a Src inhibitor ablates Akt activation and kills T. gondii. How
autophagosomes selectively target T. gondii (required for effective pathogen elimination) is unknown.
The objective of this application is to examine the role of Src in avoidance of autophagic killing of
T. gondii, understand how autophagy selectively targets the parasite and determine the relevance of
this mechanism in resistance against ocular toxoplasmosis. The central hypothesis is that inhibition of
Src enables the activation of a specific protein kinase that triggers selective autophagic targeting and
killing of T. gondii promoting protection against ocular toxoplasmosis. In the first aim we will examine
how inhibition of Src triggers activation of this protein kinase in T. gondii-infected cells. This aim will
be pursued using genetic and pharmacologic approaches that block specific signaling pathways. In
the second aim we will examine the role of this kinase in selective vs bulk autophagy in T. gondii-
infected cells. In the third aim, we will examine the molecular events controlled by this protein kinase
that explain how autophagosomes selectively target the parasite. Both aims will be pursued using a
combined approach of confocal microscopy using antibodies against endogenous proteins, live-cell
microscopy using fluorescently-tagged proteins and electron microscopy. In the fourth aim we will use
an animal model of ocular toxoplasmosis and transgenic mice to examine the role of Src, the protein
kinase controlled by Src and autophagy in ocular toxoplasmosis. The proposed work will further our
understanding of how host cell signaling regulates autophagic targeting of T. gondii and the outcome
of the infection, and may lead to adjunctive approaches to improve the treatment of toxoplasmosis.
细胞内的弓形虫是感染性视网膜炎的最常见原因
整个世界。眼弓形体病有复发的趋势,25%的患者会导致视力丧失,尤其是
在患有先天性感染的儿童中,老年人和免疫抑制者。目前的治疗方法是
不能改善视觉功能或防止复发。更好地理解
控制眼弓形体病可能会导致针对这种疾病的新的治疗方法。
自噬是溶酶体降解的一个结构性过程。弓形虫必须避免通过
自噬是为了在宿主细胞内生存。我们发现,在宿主细胞入侵期间,弓形虫
诱导EGFR信号,从而避免最初的自噬靶向。最近,我们发现
弓形虫引起持续的Src信号,维持EGFR和Akt(抑制因子)的激活
自噬)。EGFR的药理抑制触发自噬杀灭弓形虫
感染细胞,预防眼弓形体感染。然而,保护是部分的(EGFR
表达受到限制;EGFR仅部分负责Akt的激活)。相比之下,Src是
普遍存在的低浓度的Src抑制剂可以抑制Akt的激活并杀死弓形虫。多么
自噬小体选择性地靶向弓形虫(有效消除病原体所需)尚不清楚。
本应用程序的目的是研究src在避免自噬杀伤中的作用
了解自噬是如何选择性地以寄生虫为目标的,并确定
这一机制在抵抗眼弓形虫病中起着重要作用。中心假说是,抑制
SRC能够激活特定的蛋白激酶,从而触发选择性的自噬靶向和
杀灭弓形虫促进对眼弓形虫病的保护。在第一个目标中,我们将检查
抑制Src如何在弓形虫感染细胞中触发该蛋白激酶的激活。这一目标将
通过阻断特定信号通路的遗传和药理学方法进行研究。在……里面
第二个目标,我们将研究该激酶在弓形虫选择性自噬与批量自噬中的作用。
被感染的细胞。在第三个目标中,我们将研究由这种蛋白激酶控制的分子事件。
这解释了自噬是如何选择性地以寄生虫为目标的。这两个目标都将通过
利用抗内源蛋白、活细胞抗体的联合共聚焦显微镜方法
使用荧光标记蛋白质的显微镜和电子显微镜。在第四个目标中,我们将使用
眼弓形体病动物模型和转基因小鼠检测蛋白Src的作用
眼弓形体病中Src调控的激酶与自噬拟议的工作将进一步推动我们的
了解宿主细胞信号如何调节弓形虫的自噬靶向及其结果
并可能导致采用辅助方法来改进弓形虫病的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARLOS S SUBAUSTE其他文献
CARLOS S SUBAUSTE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARLOS S SUBAUSTE', 18)}}的其他基金
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease
用于控制炎症性肠病的 CD40 信号小分子抑制剂
- 批准号:
10673011 - 财政年份:2022
- 资助金额:
$ 37.65万 - 项目类别:
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease
用于控制炎症性肠病的 CD40 信号小分子抑制剂
- 批准号:
10521673 - 财政年份:2022
- 资助金额:
$ 37.65万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 37.65万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 37.65万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 37.65万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 37.65万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 37.65万 - 项目类别: